Glenmark Pharmaceuticals Ltd.

Glenmark to Launch Generic Adderall in May 2025 Amid Ongoing Shortage

a month ago

• Glenmark Pharmaceuticals will launch a generic version of Adderall tablets in five dosage strengths starting May 2025, providing a bioequivalent alternative to the reference drug by Teva Women's Health. • The generic amphetamine mixed salts product enters a market valued at approximately $421.7 million annually, according to IQVIA data for the 12-month period ending February 2025. • Company executives emphasize that this launch aims to help alleviate the ongoing Adderall shortage in the United States, addressing a significant public health concern for patients requiring this highly prescribed medication.

Glenmark Pharmaceuticals Launches Generic Vancomycin Hydrochloride Injection in US Market

2 months ago

• Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in three dosage strengths: 750 mg, 1.25 g, and 1.5 g single-dose vials. • The product is bioequivalent and therapeutically equivalent to Mylan Laboratories' reference listed drug and enters a market with annual sales of approximately $39.3 million. • This launch strengthens Glenmark's institutional portfolio as the company continues to expand its presence in the North American pharmaceutical market.

Lilly's Mounjaro Demonstrates Superior Efficacy in Head-to-Head Trials Against Diabetes Competitors

2 months ago

• Eli Lilly's Mounjaro (tirzepatide) has shown superior efficacy in reducing HbA1c levels and body weight compared to Novo Nordisk's Ozempic in clinical trials, offering new hope for the 35 million Americans with type 2 diabetes. • As the first dual-action medication that stimulates both GLP-1 and GIP receptors, Mounjaro achieved mean HbA1c reductions of 1.7% to 2.4% across trials, with participants losing between 12-25 pounds depending on dosage. • Recently launched in India following CDSCO approval, Mounjaro is now indicated for both chronic weight management in adults with obesity or overweight with comorbidities, and as an adjunct treatment for type 2 diabetes mellitus.

Glenmark Expands Diabetes Care Portfolio with Launch of Empagliflozin and Fixed-Dose Combinations in India

2 months ago

• Glenmark Pharmaceuticals has launched Empagliflozin (Glempa) and its fixed-dose combinations in India, offering new treatment options for type 2 diabetes patients with cardiovascular risks. • Clinical trials demonstrated Empagliflozin provides significant benefits including 14% reduction in major cardiovascular events, improved glycemic control, and weight loss of 2-3.8kg in combination therapies. • The Glempa product range includes three formulations: standalone Empagliflozin, Empagliflozin+Linagliptin (Glempa-L), and Empagliflozin+Metformin (Glempa-M), addressing diverse patient needs with affordable treatment options.

Glenmark Therapeutics Enters OTC Constipation Market with Polyethylene Glycol 3350 Launch

2 months ago

• Glenmark Therapeutics has launched Polyethylene Glycol 3350 powder (17 grams/capful) as an over-the-counter constipation treatment in the US market, comparable to MiraLAX®. • The company enters a lucrative market segment that generated approximately $555.7 million in annual sales for the period ending February 2025, according to Nielsen® syndicated data. • This strategic product introduction addresses growing demand for alternative suppliers in the constipation treatment category, reinforcing Glenmark's commitment to expanding its OTC healthcare portfolio.

Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost

2 months ago

• Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility. • Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet. • The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.

Glenmark Expands Injectable Portfolio with Acetylcysteine Acquisition and US Launch

3 months ago

• Glenmark Pharmaceuticals has acquired and launched Acetylcysteine Injection (6 gm/30 mL) in the US market, expanding its presence in the hospital segment through the ANDA acquisition from Aspen Pharma USA. • The newly acquired injection is therapeutically equivalent to Cumberland Pharmaceuticals' Acetadote Injection, which recorded annual sales of $15.2 million for the period ending January 2025. • Glenmark, a global pharmaceutical company operating in 80+ countries, continues to strengthen its position in respiratory, dermatology, and oncology therapeutics across branded, generic, and OTC segments.

Glenmark Pharmaceuticals Initiates Major Recall of ADHD Medication in US Market

3 months ago

• Glenmark Pharmaceuticals has initiated a recall of approximately 1.5 million bottles of an ADHD medication from the US market following FDA oversight. • The recall represents one of the larger pharmaceutical recalls in recent months, highlighting the ongoing importance of quality control in generic drug manufacturing. • This development impacts the availability of ADHD treatment options in the US market, where demand for these medications has been consistently high.

Glenmark Launches Generic Epinephrine Injection with 180-Day Exclusivity

3 months ago

• Glenmark Pharmaceuticals has launched a generic version of Epinephrine Injection USP (10 mg/10 mL) Multiple-Dose Vial, securing 180 days of competitive generic therapy exclusivity. • The product is bioequivalent to BPI Labs' reference drug and enters a market with annual sales of approximately $42.7 million as of December 2024. • This strategic launch expands Glenmark's institutional channel portfolio, reinforcing their commitment to providing affordable treatment alternatives.

Glenmark Launches Generic Clindamycin Phosphate Foam for Dermatological Treatment

3 months ago

• Glenmark Pharmaceuticals Inc., USA has introduced Clindamycin Phosphate Foam 1%, a bioequivalent generic version of Evoclin® Foam, expanding their dermatology portfolio. • The reference product Evoclin® Foam achieved annual sales of approximately $5.8 million in the 12-month period ending December 2024, indicating significant market potential. • The launch strengthens Glenmark's position in the dermatology segment, with the company maintaining presence across Branded, Generics, and OTC segments globally.

Gland Pharma Receives US FDA Approval for Latanoprost Ophthalmic Solution

6 months ago

• Gland Pharma has received US FDA approval for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), a generic equivalent to Xalatan. • The ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. • Gland Pharma plans to launch the product through its marketing partners in FY25, targeting a market with approximately $111.6 million in US sales. • This approval strengthens Gland Pharma's position in the US pharmaceutical market, expanding its portfolio of sterile injectable and ophthalmic solutions.

HPK1 Inhibitors Show Promise in Enhancing Immunotherapy for Solid Tumors

6 months ago

• HPK1 inhibition is emerging as a strategy to enhance T-cell functionality and improve immunotherapy efficacy in solid tumors, with several inhibitors in early-phase trials. • NDI-101150, a novel oral HPK1 inhibitor, has demonstrated early clinical efficacy, including a complete response in renal cell carcinoma, as both a monotherapy and in combination with pembrolizumab. • Combination therapies involving HPK1 inhibitors like BGB-15025 with checkpoint inhibitors such as tislelizumab are showing early efficacy signals, warranting further investigation. • Several HPK1 inhibitors, including GRC 54276 and CFI-402411, are in phase 1/2 trials, exploring their potential as monotherapies and in combination with pembrolizumab across various advanced solid tumors.

Ichnos Glenmark Innovation's ISB 2001 Shows Promising Results in Multiple Myeloma Trial

7 months ago

• Ichnos Glenmark Innovation's ISB 2001 demonstrated a 75% overall response rate in relapsed/refractory multiple myeloma patients during a Phase 1 clinical trial. • The trial data showed favorable safety outcomes, with no dose-limiting toxicities and only one adverse event above Grade 2 reported. • ISB 2001, a first-in-class trispecific antibody, targets BCMA and CD38 on multiple myeloma cells and CD3 on T cells. • Detailed findings will be presented at the American Society of Hematology (ASH) Annual Meeting on December 9, 2024, in San Diego.